Scipher Medicine commercializes Spectra™, a proprietary network medicine platform that analyzes blood to reveal a patient’s unique molecular disease signature and match that signature to the most effective existing therapy. The company sells tests intended to ensure providers and payers can select optimal therapy from day one for autoimmune diseases, reducing ineffective prescriptions. Molecular and clinical data generated from tested patients are used to fuel discovery and development of targeted therapeutics through pharma collaborations. Scipher emphasizes bringing precision medicine approaches—previously transformative in oncology—to autoimmune diseases where few solutions exist. The company is led by CEO Alif Saleh and is based in Waltham, Mass. Financially, Scipher announced a $110 million financing and has raised $227 million to date. Scipher Medicine is a Waltham, Mass.-based precision immunology company that matches patients to the most effective therapies using blood-based molecular signatures. It leverages a proprietary Network Medicine platform and artificial intelligence to commercialize blood tests that reveal a person's unique molecular disease signature and pair it with effective treatments. Its lead product, PrismRA, is a molecular signature test for rheumatoid arthritis that, from a routine blood draw, analyzes an individual's molecular signature to identify patients unlikely to respond adequately to TNFi therapy. This enables non-responders to be prescribed alternative, effective therapies and supports partnerships with payers, providers, and pharma across the health care value chain. Led by CEO Alif Saleh, the company intends to use the $82m Series C proceeds to expand commercial efforts for PrismRA. Scipher has raised $117m in total funding to date. Scipher Medicine has built a molecular technology platform, augmented by artificial intelligence, that produces diagnostic tests to predict drug response in autoimmune disease. Its lead product, PrismRA, predicts response to anti-TNF therapies in rheumatoid arthritis patients and aims to enable physicians to prescribe effective drugs from day one. The company cites that over 65% of patients fail to respond adequately to anti-TNF drugs, which PrismRA is designed to address. Scipher has announced positive results for PrismRA earlier this year and has launched a prospective trial to confirm the test's clinical utility. Financially, the company has raised $30 million to date to fund development and commercialization of PrismRA. Scipher is privately held and headquartered in Waltham, Massachusetts. Scipher Medicine has built a molecular technology platform that interprets RNA and protein expression data from a patient’s blood or tissue sample to reveal the molecular processes driving disease. The platform generates patient-specific disease signatures and screens drugs to determine which therapies target those signatures, enabling prediction of individual drug response. It targets both diagnostic and therapeutic opportunities, including identifying targets for new drug development. The company is led by CEO Alif Saleh and was co-founded by Dr. Joseph Loscalzo and Dr. Albert-Laszlo Barabasi. Scipher is based in Waltham, MA. Financially, the company completed a Series A and has raised a total of $10M to date.

Total raised

$192M

Funding rounds

4

Latest round

Equity

Latest activity

Feb 2022